Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GMED
stocks logo

GMED

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
777.51M
+18.29%
1.058
+25.93%
726.05M
+21.39%
0.872
+28.24%
776.79M
+4.22%
0.968
+12.59%
Estimates Revision
The market is revising Upward the revenue expectations for Globus Medical, Inc. (GMED) for FY2025, with the revenue forecasts being adjusted by 0.06% over the past three months. During the same period, the stock price has changed by 47.19%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.06%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.05%
In Past 3 Month
Stock Price
Go Up
up Image
+47.19%
In Past 3 Month
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 92.22 USD with a low forecast of 64.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 92.22 USD with a low forecast of 64.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 88.740
sliders
Low
64.00
Averages
92.22
High
114.00
Current: 88.740
sliders
Low
64.00
Averages
92.22
High
114.00
Morgan Stanley
Patrick Wood
Overweight
maintain
$70 -> $100
2025-12-02
New
Reason
Morgan Stanley
Patrick Wood
Price Target
$70 -> $100
2025-12-02
New
maintain
Overweight
Reason
Morgan Stanley analyst Patrick Wood raised the firm's price target on Globus Medical to $100 from $70 and keeps an Overweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Truist
Buy
maintain
$93 -> $105
2025-11-18
Reason
Truist
Price Target
$93 -> $105
2025-11-18
maintain
Buy
Reason
Truist raised the firm's price target on Globus Medical to $105 from $93 and keeps a Buy rating on the shares. The firm cites multiple expansion in the comp group for the price target update.
Piper Sandler
Matt O'Brien
Overweight
maintain
$80 -> $90
2025-11-07
Reason
Piper Sandler
Matt O'Brien
Price Target
$80 -> $90
2025-11-07
maintain
Overweight
Reason
Piper Sandler analyst Matt O'Brien raised the firm's price target on Globus Medical to $90 from $80 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 results with sales and adjusted EPS landing above expectations. Management raised full year guidance on the top- and bottom-lines by more than the beat instilling confidence in the remainder of the year.
Wells Fargo
NULL -> Overweight
maintain
$66 -> $79
2025-11-07
Reason
Wells Fargo
Price Target
$66 -> $79
2025-11-07
maintain
NULL -> Overweight
Reason
Wells Fargo raised the firm's price target on Globus Medical to $79 from $66 and keeps an Overweight rating on the shares. The firm notes the company delivered impressive Q3 beat with EPS of $1.18 vs. consensus 78c. Raised 2025 targets reflect Nevro accretion earlier than expected and U.S. Spine stabilization.
Barclays
Matt Miksic
Overweight
maintain
$106 -> $114
2025-11-07
Reason
Barclays
Matt Miksic
Price Target
$106 -> $114
2025-11-07
maintain
Overweight
Reason
Barclays analyst Matt Miksic raised the firm's price target on Globus Medical to $114 from $106 and keeps an Overweight rating on the shares. The firm upped estimates following the company's "impressive" Q3 beat.
RBC Capital
Shagun Singh
Outperform
maintain
$88 -> $92
2025-11-07
Reason
RBC Capital
Shagun Singh
Price Target
$88 -> $92
2025-11-07
maintain
Outperform
Reason
RBC Capital analyst Shagun Singh raised the firm's price target on Globus Medical to $92 from $88 and keeps an Outperform rating on the shares. The company issued solid Q3 results, delivering sales beat of 5% and a robust EPS beat of 51%, driven by solid operational execution that drove 9.6% y/y growth in U.S. spine and better-than-expected Nevro contribution, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Globus Medical Inc (GMED.N) is 22.05, compared to its 5-year average forward P/E of 26.34. For a more detailed relative valuation and DCF analysis to assess Globus Medical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
26.34
Current PE
22.05
Overvalued PE
33.04
Undervalued PE
19.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
13.42
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.23
Undervalued EV/EBITDA
9.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.88
Current PS
0.00
Overvalued PS
6.73
Undervalued PS
3.04
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

GMED News & Events

Events Timeline

(ET)
2025-11-07
12:00:03
Globus Medical Sees 33.2% Increase
select
2025-11-07
10:00:03
Globus Medical Sees 31.6% Increase
select
2025-11-06 (ET)
2025-11-06
16:44:37
Globus Medical increases FY25 adjusted EPS forecast to $3.75-$3.85, up from $3.00-$3.30
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.0
07:13 AMYahoo Finance
Is It Still Worth Considering Globus Medical Following Its Recent 43.9% Increase?

  • Stock Performance: Globus Medical's stock has seen significant fluctuations, with a recent 2.6% decline following a 43.9% increase over the past month, while maintaining gains of 23.8% over three years and 48.3% over five years.

  • Valuation Concerns: The company scores only 2/6 on valuation checks, with a Discounted Cash Flow (DCF) analysis suggesting it is overvalued by approximately 414.3%, estimating an intrinsic value of $17.26 per share compared to its current trading price of around $88.

  • PE Ratio Analysis: Globus Medical's price-to-earnings (PE) ratio is about 28.0x, which is in line with the industry average but above its fair ratio of 23.8x, indicating that the stock may be expensively valued based on its earnings growth outlook.

  • Narrative Approach to Valuation: Investors can create personalized narratives about Globus Medical's future performance, which can lead to varying fair value estimates, ranging from $65 to $106 per share, depending on assumptions about growth and risks.

[object Object]
Preview
7.5
12-02NASDAQ.COM
HSIC Stock Gains from Enhanced Collaboration with vVARDIS

  • Expansion of Distribution Rights: Henry Schein, Inc. has secured exclusive U.S. distribution rights for the drill-free Curodont Repair Fluoride Plus product, effective January 1, 2026, which is expected to enhance its Dental business and support stock momentum.

  • Market Growth and Health Impact: The global dental caries treatment market is projected to grow significantly, driven by the rising prevalence of dental diseases and the introduction of innovative treatment options like Curodont, which addresses early-stage cavities without traditional drilling.

  • Strategic Partnerships: The company has also formed a strategic partnership with Oral Genome to distribute advanced salivary testing nationwide, further expanding its service offerings in the dental sector.

  • Stock Performance and Rankings: Henry Schein's shares have seen a slight increase, and the company holds a Zacks Rank #3 (Hold), while other medical stocks like Globus Medical and Boston Scientific are performing better in the market.

[object Object]
Preview
5.0
12-01NASDAQ.COM
HSIC Shares Poised to Gain from Launch of Henry Schein One's Workflow

  • AI Integration in Dental Software: Henry Schein One has introduced AI and automation workflows, including Voice Notes, at the 2025 Greater New York Dental Meeting, enhancing practice efficiency and revenue management through better claims processing and patient communication.

  • Partnership with AWS: The company has partnered with Amazon Web Services to integrate generative AI technologies across its platforms, aiming to improve the overall dental experience from patient intake to treatment planning.

  • Market Performance and Growth: Despite a recent 1.2% drop in shares, Henry Schein's stock has seen a 15.4% increase over the past month, with projected earnings growth of 3.6% for 2025, supported by strong sales and operational improvements.

  • Innovative Features for Practices: New features like the Forms workflow and Detect AI enhance patient data accuracy and diagnostic confidence, while multilingual support and real-time transcription reduce administrative burdens, allowing dental teams to focus more on patient care.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Globus Medical Inc (GMED) stock price today?

The current price of GMED is 88.74 USD — it has increased 1.13 % in the last trading day.

arrow icon

What is Globus Medical Inc (GMED)'s business?

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.

arrow icon

What is the price predicton of GMED Stock?

Wall Street analysts forecast GMED stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMED is 92.22 USD with a low forecast of 64.00 USD and a high forecast of 114.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Globus Medical Inc (GMED)'s revenue for the last quarter?

Globus Medical Inc revenue for the last quarter amounts to 769.05M USD, increased 22.91 % YoY.

arrow icon

What is Globus Medical Inc (GMED)'s earnings per share (EPS) for the last quarter?

Globus Medical Inc. EPS for the last quarter amounts to 0.88 USD, increased 131.58 % YoY.

arrow icon

What changes have occurred in the market's expectations for Globus Medical Inc (GMED)'s fundamentals?

The market is revising Upward the revenue expectations for Globus Medical, Inc. (GMED) for FY2025, with the revenue forecasts being adjusted by 0.06% over the past three months. During the same period, the stock price has changed by 47.19%.
arrow icon

How many employees does Globus Medical Inc (GMED). have?

Globus Medical Inc (GMED) has 5300 emplpoyees as of December 05 2025.

arrow icon

What is Globus Medical Inc (GMED) market cap?

Today GMED has the market capitalization of 11.74B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free